drug
XTANDI
updated 6mo agoby Astellas Pharma Inc
community read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
Trials studying XTANDI
- phase2An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- phase2Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- phase3Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- phase2Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
- phase2The COSMYC Trial (COmbined Suppression of MYC)
- phase1A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
- phase3An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- phase3A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
News(8)
- AstraZeneca cuts early-phase prostate cancer pipelineAstraZeneca has punted a pair of early-phase prostate cancer programs as part of its quarterly pipeline clear out.fiercebiotech · 20d ago
- Lilly shuffles business structure; Novartis writes off part of Avidity dealLilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.biopharma_dive · 22d ago
- Astellas links up with AI Proteins in $400M computational drug discovery dealJapan's Astellas Pharma has tapped Boston computational discovery company AI Proteins in a drug discovery deal potentially worth $400 million.fiercebiotech · 29d ago
- Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEsLooking to expand its oncology portfolio, Gilead has tapped Vir Biotechnology’s masked T-cell engager tech in a potential $1.9 billion biobucks deal.fiercebiotech · 1mo ago
- Kairos seizes moment to push prostate cancer prospect into earlier settingKairos Pharma is moving prostate cancer prospect ENV-105 into an earlier line of treatment in response to midphase survival data.fiercebiotech · 1mo ago
- Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchSome analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.biopharma_dive · 3mo ago
- Alpha-Emitting Therapies in Metastatic Castration-Resistant Prostate CancerDr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of alpha-emitting radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC), with a focus on radium…onclive · 6mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 6mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that